Group items matching

in title, tags, annotations or url

How To Relieve Constipation Fast? About twelve percent of the population worldwide report constipation each year. It is characterized by undue effort and time to expel the stool. Here we discuss some useful home remedies to treat constipation. Sometimes it can be really stubborn and won't go away.

An average human being visits the toilet six times a day and stays there for about two minutes. However, attending the call of nature is not always this easy. Sometimes, a common gastrointestinal condition called constipation occurs. It becomes difficult to expel the feces. A desire to visit the washroom is not enough to physically eliminate the feces.

Erectile dysfunction, or ED, is the most common sex problem that men report to their doctor. It affects as many as 30 million men.ED is defined as trouble getting or keeping an erection that's firm enough for sex. Though it's not rare for a man to have some problems with erections from time to time, ED that is progressive or happens routinely with sex is not normal, and it should be treated.

Psoriasis is a chronic skin condition that accelerates the rate at which your skin cells grow. An effective method to treat psoriasis is phototherapy or light therapy.

Psoriasis is an auto-immune illness that affects almost three percent of the world's population. People who suffer from psoriasis experience a great deal of skin irritation and discomfort.

Book appointment with the best Nephrologist in Medanta Dr. Shyam Bansal Medanta is an Associate director in the department of Nephrology at Medanta hospital. Dr. Shyam Bansal Medanta has treated several patients in India. He is a member of prestigious medical associations. he helped several patients to recover from various disorders.    Book appointment online with Dr. Shyam Bansal Medanta only on Credihealth.

The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) medicine. The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a treatment for overactive bladder available for women without the need for a prescription. Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022. It would be the first time a medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses. After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.

Maxwellia has revealed its plans to switch some of its medicines in the self-care category from prescription-only-medicine (POM) to a pharmacy (P) medicine. After authorising the switch of Maxwellia's two brands of desogestrel contraceptive pills, Lovima and Hana, MHRA has opened a public consultation on reclassification of Aquiette (overactive bladder treatment) 2.5mg tablets manufactured by the company to be made available from pharmacies. "Maxwellia is currently looking at a number of medicines which treat a range of conditions in major public health categories that can be 'switched' from needing a prescription to being conveniently bought at a local high street or supermarket pharmacy. With its foot firmly on the accelerator it has other applications under assessment with the MHRA, including women's health products," the company stated in a recent statement. "Push to convert more prescription medicines to pharmacy medicines will firmly position pharmacists at heart of nation's public health, helping futureproof NHS," the medicine said.

Wales has begun the rolled-out of a community pharmacy prescribing service as part of reforms agreed by the Welsh health minister last December. Eluned Morgan approved wide-ranging changes following re-negotiation of the Community Pharmacy Contractual Framework with Community Pharmacy Wales, the representative body for community pharmacies in Wales. The roll out will allow appropriately trained community pharmacists to treat an extended range of conditions that currently require people to visit their GP. Initially pharmacist prescribers will be able to prescribe medicines, including antibiotics for acute illnesses like urinary tract and upper respiratory tract infections, and also prescribe routine contraception. The first of its kind in the UK, the service is being rolled out progressively across Wales, building on local schemes which are already in place.

Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, a recent study has revealed. The research has been published in the 'British Journal of Psychiatry Open'. A systematic review led by the University of Exeter and funded by the Medical Research Council analysed evidence from 83 published research papers. The strongest evidence emerged around the use of ketamine to treat both major depression and bipolar depression. Symptoms were reduced as swiftly as one to four hours after a single treatment and lasted up to two weeks. Some evidence suggested that repeated treatment may prolong the effects, however more high-quality research is needed to determine by how long. Similarly, single or multiple doses of ketamine resulted in moderate to large reductions in suicidal thoughts. This improvement was seen as early as four hours following ketamine treatment and lasted on average three days, and up to a week.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

Indian drugmaker Dr Reddy's Laboratories will launch its generic version of Merck's antiviral Covid-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday (January 4). The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700. "Molflu is expected to be available from early next week in pharmacies throughout (India) with particular focus on states with high caseload of Covid-19," the company spokesperson said. India last week gave emergency use approval to along with two vaccines, as the country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant.

Provision of free lateral flow tests could end in the UK, and prime minister Boris Johnson is expected to make the big announcement within weeks, The Sunday Times has reported. The report said that in future free test kits could be provided only in high-risk settings such as care homes, hospitals and schools, and to people with symptoms, and contact tracing by NHS Test and Trace is also expected to be scaled back. The newspaper quoted a senior Whitehall source as saying: "I don't think we are in a world where we can continue to hand out free lateral flow tests to everybody. "It's likely we will move to a scenario where there is less testing, but we have a capacity to ramp it up if necessary." It added that more than £6 billion of public money has already been spent on mass testing. Separately, Dr Clive Dix, former chairman of the country's vaccine task force said that Covid-19 should now be treated as a flu, and mass vaccination campaigns should end after the booster shots in the UK.

Diamorphine 5mg and 10mg powder used for solution for injection ampoules will remain unavailable until February 2022, Department of Health and Social Care (DHSC) has said in an update. These injection ampoules are used to treat severe pain associated with surgical procedures, pain in the terminally ill, and to provide relief in acute pulmonary oedema. Diamorphine 30mg and 100mg ampoules are available, however, the stock is not enough to support an uplift in demand. Separately, the DHSC has extended the Medicine Supply Notification for Kolanticon gel, which is expected to remain unavailable until October 2022.

An international specialty pharmaceutical group, Essential Pharma has announced the completion of two transactions with fellow UK-based Rosemont Pharmaceuticals. The company completed the divestment of its oral liquid portfolio to Rosemont, and acquired a series of attractive, niche products with "geographic expansion potential." Commenting on the announcement, Essential Pharma chief executive Steen Vangsgaard said: "The Rosemont products bring additional niche products into our portfolio with international expansion potential. "The divestiture of our UK oral liquid products streamlines our portfolio, allowing us to focus and accelerate our strategic growth ambition of building a leading international specialty pharma platform." Under the divestment deal, Rosemont Pharmaceuticals will acquire the product portfolio of licences, registrations and trademarks, as well as related commercial rights, to a number of oral generic products which are used to treat a range of conditions in various therapeutic areas.

Health secretary Sajid Javid vouches support for a "pharmacy first" model of care for minor illnesses, to help clear the backlog of NHS care arising due to the Covid-19 pandemic. Speaking at the National Pharmacy Association's (NPA) centenary dinner in central London on Wednesday (November 24), Javid said he wanted to "go further" than existing services like the NHS Community Pharmacist Consultation Service, to make it "quicker and easier" for people to access primary care. He said: "I want to see how much further we can go. That's one of the reasons why we're working up plans for a pharmacy first model in England that will direct more patients directly to pharmacies without having to go to see their GPs. This will help us to beat the backlog and make sure that even more people can benefit from (pharmacists') brilliant advice and care." Expressing his commitment to transform every aspect of health and care in the country he said that community pharmacies should be "at the very heart of primary care - not just treating people but preventing people from becoming patients in the first place."

Hypovase (prazosin) 500 microgram tablets, manufactured by drug major Pfizer, will remain out of stock until mid-January 2022 due to a manufacturing issue. The Department of Health and Social Care (DHSC) and NHS England and Improvement (NHSE&I) have issued a supply disruption alert for the medicine that is used to treat heart-related troubles. Pfizer, the sole supplier of prazosin 500mg tablets in the UK, is out of stock from late November 2021, and had discontinued the Hypovase® (prazosin) 1mg tablets in May 2021. Advice for healthcare professionals In the given situation, prescribers need to review all affected patients to discuss management plans. Meanwhile, alternative medicine alpha blockers remain available to support an uplift in demand.

Prime minister Boris Johnson received his Covid-19 booster shot on Thursday (December 2) and urged others to follow suit to help the country fend off the Omicron variant of coronavirus. Wearing a mask, Johnson briefly chatted to staff and others queuing for their shots at the vaccination centre in central London, asking them if they were there to receive a booster dose and thanking them for attending. Johnson, who said it could "have gone either way" when he was treated in hospital for Covid last year, was later filmed rolling up his shirt sleeve and receiving his shot. "Fantastic. Thank you so much," he said to the nurse, before receiving a badge that said "I've boosted my immunity".

GSK is helping pharmacists to tap into Self Care Week this November, and remind patients how they can adopt a more proactive approach in looking after their health. This includes treating ailments, such as joint pain, over the counter to take pressure off GPs where possible. Joint pain complaints take up a significant amount of general practice resource with 57 per cent of pain presentations reported relating to joint pain[1], as well as 23 per cent of sufferers feeling as though their pain impacts their quality of life[2]. Many of these complaints and ailments could be addressed with treatment recommendations from a pharmacist with support from Voltarol. GSK, manufacturer of Voltarol (the market leader in the pain relief topic category[3]), offers support through both its products and resources in hopes to advocate over-the-counter treatments.

Community Pharmacy Wales and the Welsh government have entered an agreement on Thursday (December 16), enabling all pharmacies to deliver provision of contraception, treatment for common minor ailments, and access to repeat medicines in an emergency. Expansion of clinical community pharmacy service will be supported with an increased funding of £20 million a year by April 2024 from the current level of £11.4m. The two bodies have been negotiating the terms of agreement, which also includes plans to roll out a Wales-wide pharmacy prescribing service, allowing trained pharmacists to treat an extended range of conditions that currently require GP visits. The agreement will allow patients to access NHS services closer to home which in turn would free up GP and other NHS services for patients with more complex needs. Eluned Morgan MS, minister for Health and Social Services said: "I welcome the positive approach to negotiations taken by Community Pharmacy Wales, embracing our ambition for a reimagined community pharmacy service, which is an integral part of a strong primary care landscape."

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four drug candidates intended for use as licensed pain medications. The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome. The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to confirm its value as a potential drug. Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.